About US
Contact us
-
Amgen tops forecasts for Q4, thanks to new drugs and higher pricesAmgen ($AMGN) profits beat analyst expectations. And its sales grew by 11% in the fourth quarter. That's a feat, considering some of its biggest products--the anemia drugs Epogen and Aranesp--continu2013/1/25
-
Novartis braces for $3.5B hit to 2013 salesFlat sales and lower profits. These aren't predictions that shareholders like to hear. But like other Big Pharmas before it, Novartis ($NVS) faces generic competition for its biggest drugs. And like2013/1/24
-
Celgene's Abraxane shows promise in pancreatic cancerA drug that Celgene ($CELG) acquired in its $2.9 billion acquisition of Abraxis BioScience in 2010 is showing promise against the notoriously hard-to-treat pancreatic cancer. The disease kills 38,2013/1/24
-
FDA approval smooths way to more Botox salesWhile Botox still primarily springs to mind as a cosmetic treatment for wrinkles, the Allergan ($AGN) drug has been approved for 26 indications in 85 countries. The latest, and one it has been longin2013/1/23
-
Novo ready to rev up Tresiba for European launchNovo Nordisk ($NVO) is ready to roll with its new diabetes drug Tresiba--in Europe, at least. The company won regulatory approval for the potential blockbuster yesterday, setting up a mano-a-mano fig2013/1/23
-
Top pharmacists gather for conferenceA number of top independent pharmaceutical companies are set to gather for a conference this February in order to develop strategies that will enable progress in a radically changing health market.2013/1/22
-
BioChemics patents wound healing treatmentThe US Patent and Trademark office has issued a new patent for 'Methods and Compositions for Topical Treatment of Medical Conditions Including Wounds and Inflammation' on behalf of pharmaceutical firm2013/1/22
-
DSM Announces License Agreement with Amgen for Use of DSM's XD® Cell Culture PatentsDSM Pharmaceutical Products, the custom manufacturing and technology business of Royal DSM (NYSE, Euronext: DSM KON), announced today that it has signed a non-exclusive license agreement with Amgen I2013/1/21
-
Pfizer's Bosulif set for greater sales with EMA approvalPfizer ($PFE) has extended the run of good news for its focus on targeted cancer treatment with a positive recommendation from EU regulators for Bosulif. The nod sets the stage for another approval a2013/1/21
-
Drugmakers beware, Costco now in pharmacy benefitsIn the evolving drug payer world, pharmacy benefit managers (PBM) are commanding a bigger role. Now drug companies have a new and interesting PBM with which to contend--Costco. The discounter has s2013/1/18